As a Strategic Hospital Advisor for RxBenefits, specializing in 340B, Sarah Hearn works with hospitals and health systems to help them leverage 340B to reduce their overall employee drug spend, as well as with commercial employers to mitigate the effect of 340B-related rebate loss to their pharmacy plan. She expands on her thoughts below.
Can you give a brief background on the 340B Drug Pricing Program, and the goal of the program?
The federal 340B Drug Pricing Program was enacted in 1992 in a bipartisan effort to enable safety-net health care institutions to stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services. The law requires drug manufacturers to offer discounted prices (roughly 20%-60% below Wholesale Acquisition Cost, or WAC) to eligible safety-net health care facilities on certain outpatient drugs. In return, congress approved having Medicaid and Medicare Part B cover the participating manufacturers' product, a deal that has been highly profitable for drug manufacturers.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
- Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
- Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
Already have an account? Sign In
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
